Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-177 oxodotreotide with or without bevacizumab versus bevacizumab in somatostatin receptor-positive recurrent refractory meningioma
CTR20263857Phase 3Active
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate, bevacizumab in meningioma, sponsored by Sinotau Pharmaceutical Group. Started Oct 2026; status: active.
02
Drugs
lutetium Lu 177 dotatatebevacizumab
03
Conditions
meningioma
Beyond the preview
Go deeper on CTR20263857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263857.